

Taro Yamashita

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4015940/publications.pdf>

Version: 2024-02-01

86
papers

5,164
citations

201385

27
h-index

88477

70
g-index

89
all docs

89
docs citations

89
times ranked

6735
citing authors

#	ARTICLE	IF	CITATIONS
1	BMP9-ID1 Signaling Activates HIF-1 α and VEGFA Expression to Promote Tumor Angiogenesis in Hepatocellular Carcinoma. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1475.	1.8	14
2	Liver-related events after direct-acting antiviral therapy in patients with hepatitis C virus-associated cirrhosis. <i>Journal of Gastroenterology</i> , 2022, 57, 120-132.	2.3	20
3	Phosphorylation of hTERT at threonine 249 is a novel tumor biomarker of aggressive cancer with poor prognosis in multiple organs. <i>Journal of Pathology</i> , 2022, 257, 172-185.	2.1	7
4	Oral Corticosteroids Impair Mucin Production and Alter the Posttransplantation Microbiota in the Gut. <i>Digestion</i> , 2022, 103, 269-286.	1.2	1
5	Dickkopf-1 Promotes Angiogenesis and is a Biomarker for Hepatic Stem Cell-like Hepatocellular Carcinoma. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2801.	1.8	13
6	Peptide vaccine-treated, long-term surviving cancer patients harbor self-renewing tumor-specific CD8 ⁺ T cells. <i>Nature Communications</i> , 2022, 13, .	5.8	8
7	Preexisting Humoral Immunity Cross-Reacting with SARS-CoV-2 Might Prevent Death Due to COVID-19 in Critical Patients. <i>Journal of Clinical Medicine</i> , 2022, 11, 3870.	1.0	2
8	Sofosbuvir plus velpatasvir treatment for hepatitis C virus in patients with decompensated cirrhosis: a Japanese real-world multicenter study. <i>Journal of Gastroenterology</i> , 2021, 56, 67-77.	2.3	34
9	Safety and efficacy of sorafenib followed by regorafenib or lenvatinib in patients with hepatocellular carcinoma. <i>Hepatology Research</i> , 2021, 51, 190-200.	1.8	9
10	Effect of adoptive T-cell immunotherapy on immunological parameters and prognosis in patients with advanced pancreatic cancer. <i>Cytotherapy</i> , 2021, 23, 137-145.	0.3	10
11	Interdisciplinary groups perform better than intradisciplinary groups in online group discussion activities. <i>Medical Education Online</i> , 2021, 26, 1886649.	1.1	6
12	DOCK11 and DENND2A play pivotal roles in the maintenance of hepatitis B virus in host cells. <i>PLoS ONE</i> , 2021, 16, e0246313.	1.1	8
13	The characteristics of the immune cell profiles in peripheral blood in cholangiocarcinoma patients. <i>Hepatology International</i> , 2021, 15, 695-706.	1.9	7
14	Serum Laminin β 2 Monomer as a Diagnostic and Predictive Biomarker for Hepatocellular Carcinoma. <i>Hepatology</i> , 2021, 74, 760-775.	3.6	21
15	BMP9-ID1 signaling promotes EpCAM-positive cancer stem cell properties in hepatocellular carcinoma. <i>Molecular Oncology</i> , 2021, 15, 2203-2218.	2.1	14
16	Establishment of liver tumor cell lines from atherogenic and high fat diet fed hepatitis C virus transgenic mice. <i>Scientific Reports</i> , 2021, 11, 13021.	1.6	1
17	Liver cancer stem cells: Recent progress in basic and clinical research. <i>Regenerative Therapy</i> , 2021, 17, 34-37.	1.4	11
18	Restorative effect of adipose tissue-derived stem cells on impaired hepatocytes through Notch signaling in non-alcoholic steatohepatitis mice. <i>Stem Cell Research</i> , 2021, 54, 102425.	0.3	6

#	ARTICLE	IF	CITATIONS
19	A case of traumatic diaphragmatic hernia that caused obstruction of middle hepatic vein. <i>Acta Hepatologica Japonica</i> , 2021, 62, 413-419.	0.0	0
20	Expression of Cancer Stem Cell Markers EpCAM and CD90 Is Correlated with Anti- and Pro-Oncogenic EphA2 Signaling in Hepatocellular Carcinoma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8652.	1.8	10
21	Chronic liver disease enables gut <i>Enterococcus faecalis</i> colonization to promote liver carcinogenesis. <i>Nature Cancer</i> , 2021, 2, 1039-1054.	5.7	26
22	Clinical trial of autologous adipose tissue-derived regenerative (stem) cells therapy for exploration of its safety and efficacy. <i>Regenerative Therapy</i> , 2021, 18, 97-101.	1.4	12
23	Dysbiotic gut microbiota in pancreatic cancer patients form correlation networks with the oral microbiota and prognostic factors. <i>American Journal of Cancer Research</i> , 2021, 11, 3163-3175.	1.4	4
24	Characterization of adipose tissue-derived stromal cells of mice with nonalcoholic fatty liver disease and their use for liver repair. <i>Regenerative Therapy</i> , 2021, 18, 497-507.	1.4	2
25	Direct-Acting Antiviral Agents Reduce the Risk of Malignant Transformation of Hepatobiliary Phase-Hypointense Nodule without Arterial Phase Hyperenhancement to Hepatocellular Carcinoma on Gd-EOB-DPTA-Enhanced Imaging in the Hepatitis C Virus-Infected Liver. <i>Liver Cancer</i> , 2020, 9, 261-274.	4.2	5
26	Combination of gemcitabine and anti-PD-1 antibody enhances the anticancer effect of M1 macrophages and the Th1 response in a murine model of pancreatic cancer liver metastasis. , 2020, 8, e001367.		62
27	Safety and Long-Term Outcome of Intratumoral Injection of OK432-Stimulated Dendritic Cells for Hepatocellular Carcinomas After Radiofrequency Ablation. <i>Translational Oncology</i> , 2020, 13, 100777.	1.7	17
28	Effects of adaptive immune cell therapy on the immune cell profile in patients with advanced gastric cancer. <i>Cancer Medicine</i> , 2020, 9, 4907-4917.	1.3	2
29	IL-28B variant as a predictor in patients with advanced hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1813-1820.	1.4	2
30	CDK1 dependent phosphorylation of hTERT contributes to cancer progression. <i>Nature Communications</i> , 2020, 11, 1557.	5.8	38
31	Inactivation of Transcriptional Repressor Capicua Confers Sorafenib Resistance in Human Hepatocellular Carcinoma. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2020, 10, 269-285.	2.3	14
32	A novel Î±-fetoprotein-derived helper T-lymphocyte epitope with strong immunogenicity in patients with hepatocellular carcinoma. <i>Scientific Reports</i> , 2020, 10, 4021.	1.6	6
33	Fatty acid-driven modifications in T-cell profiles in non-alcoholic fatty liver disease patients. <i>Journal of Gastroenterology</i> , 2020, 55, 701-711.	2.3	16
34	Tumor lysis syndrome in a patient with metastatic melanoma treated with nivolumab. <i>Clinical Journal of Gastroenterology</i> , 2020, 13, 935-939.	0.4	7
35	Management of biliary stricture in patients with IgG4-related sclerosing cholangitis. <i>PLoS ONE</i> , 2020, 15, e0232089.	1.1	7
36	Comparative analysis of liver functional reserve during lenvatinib and sorafenib for advanced hepatocellular carcinoma. <i>Hepatology Research</i> , 2020, 50, 871-884.	1.8	35

#	ARTICLE	IF	CITATIONS
37	Regenerative Therapy for Liver Cirrhosis Based on Intrahepatic Arterial Infusion of Autologous Subcutaneous Adipose Tissue-Derived Regenerative (Stem) Cells: Protocol for a Confirmatory Multicenter Uncontrolled Clinical Trial. <i>JMIR Research Protocols</i> , 2020, 9, e17904.	0.5	6
38	Management of biliary stricture in patients with IgG4-related sclerosing cholangitis. , 2020, 15, e0232089.		0
39	Management of biliary stricture in patients with IgG4-related sclerosing cholangitis. , 2020, 15, e0232089.		0
40	Management of biliary stricture in patients with IgG4-related sclerosing cholangitis. , 2020, 15, e0232089.		0
41	Management of biliary stricture in patients with IgG4-related sclerosing cholangitis. , 2020, 15, e0232089.		0
42	Surrogacy of Time to Progression for Overall Survival in Advanced Hepatocellular Carcinoma Treated with Systemic Therapy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Liver Cancer</i> , 2019, 8, 130-139.	4.2	21
43	Characteristics of Immune Response to Tumor-Associated Antigens and Immune Cell Profile in Patients With Hepatocellular Carcinoma. <i>Hepatology</i> , 2019, 69, 653-665.	3.6	56
44	Three renal failure cases successfully treated with ombitasvir/paritaprevir/ritonavir for genotype 1b hepatitis C virus reinfection after liver transplantation. <i>Clinical Journal of Gastroenterology</i> , 2019, 12, 63-70.	0.4	4
45	Distinct chemotherapy-associated anti-cancer immunity by myeloid cells inhibition in murine pancreatic cancer models. <i>Cancer Science</i> , 2019, 110, 903-912.	1.7	11
46	Adipose tissue-derived stem cells prevent fibrosis in murine steatohepatitis by suppressing IL-17-mediated inflammation. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 1432-1440.	1.4	18
47	Development of novel diagnostic system for pancreatic cancer, including early stages, measuring $\langle \text{scp} \rangle$ mRNA of whole blood cells. <i>Cancer Science</i> , 2019, 110, 1364-1388.	1.7	17
48	Characteristics of Impaired Dendritic Cell Function in Patients With Hepatitis B Virus Infection. <i>Hepatology</i> , 2019, 70, 25-39.	3.6	26
49	Gut-derived <i>Enterococcus faecium</i> from ulcerative colitis patients promotes colitis in a genetically susceptible mouse host. <i>Genome Biology</i> , 2019, 20, 252.	3.8	78
50	Gadoxetic acid-enhanced magnetic resonance imaging reflects co-activation of β -catenin and hepatocyte nuclear factor 4 α in hepatocellular carcinoma. <i>Hepatology Research</i> , 2018, 48, 205-216.	1.8	28
51	Serum <i>Wisteria floribunda</i> agglutinin-positive Mac-2 binding protein predicts hepatocellular carcinoma incidence and recurrence in nucleos(t)ide analogue therapy for chronic hepatitis B. <i>Journal of Gastroenterology</i> , 2018, 53, 740-751.	2.3	17
52	Analysis of the liver functional reserve of patients with advanced hepatocellular carcinoma undergoing sorafenib treatment: Prospects for regorafenib therapy. <i>Hepatology Research</i> , 2018, 48, 956-966.	1.8	39
53	Surrogacy of time to prgression for overall survival in advanced hepatocellular carcinoma treated with systemic therapy: A systematic review and meta-analysis of randomized controlled trials.. <i>Journal of Clinical Oncology</i> , 2018, 36, 403-403.	0.8	0
54	The evolving concept of liver cancer stem cells. <i>Molecular Cancer</i> , 2017, 16, 4.	7.9	181

#	ARTICLE	IF	CITATIONS
55	De Novo Emergence of Mesenchymal Stem-Like CD105 + Cancer Cells by Cytotoxic Agents in Human Hepatocellular Carcinoma. <i>Translational Oncology</i> , 2017, 10, 184-189.	1.7	14
56	Sorafenib suppresses extrahepatic metastasis de novo in hepatocellular carcinoma through inhibition of mesenchymal cancer stem cells characterized by the expression of CD90. <i>Scientific Reports</i> , 2017, 7, 11292.	1.6	24
57	Peretinoin, an acyclic retinoid, inhibits hepatocarcinogenesis by suppressing sphingosine kinase 1 expression in vitro and in vivo. <i>Scientific Reports</i> , 2017, 7, 16978.	1.6	25
58	Beneficial Effect of Maintaining Hepatic Reserve during Chemotherapy on the Outcomes of Patients with Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2017, 6, 236-249.	4.2	24
59	Prognosis of type 1 autoimmune pancreatitis after corticosteroid therapy-induced remission in terms of relapse and diabetes mellitus. <i>PLoS ONE</i> , 2017, 12, e0188549.	1.1	27
60	Serum cytokine profiles predict survival benefits in patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective cohort study. <i>BMC Cancer</i> , 2017, 17, 870.	1.1	25
61	Sporadic PCDH18 somatic mutations in EpCAM-positive hepatocellular carcinoma. <i>Cancer Cell International</i> , 2017, 17, 94.	1.8	4
62	Potential efficacy of therapies targeting intrahepatic lesions after sorafenib treatment of patients with hepatocellular carcinoma. <i>BMC Cancer</i> , 2016, 16, 338.	1.1	12
63	Postâ€progression survival and progressionâ€free survival in patients with advanced hepatocellular carcinoma treated by sorafenib. <i>Hepatology Research</i> , 2016, 46, 650-656.	1.8	66
64	Response to chemotherapy improves hepatic reserve for patients with hepatocellular carcinoma and Childâ€Pugh B cirrhosis. <i>Cancer Science</i> , 2016, 107, 1263-1269.	1.7	22
65	Stemness of liver cancer: From hepatitis B virus to Wnt activation. <i>Journal of Hepatology</i> , 2016, 65, 873-875.	1.8	6
66	Identification of microRNAs specific for epithelial cell adhesion moleculeâ€positive tumor cells in hepatocellular carcinoma. <i>Hepatology</i> , 2015, 62, 829-840.	3.6	51
67	A Fluorescent Imaging Probe Based on a Macrocyclic Scaffold That Binds to Cellular EpCAM. <i>Journal of Molecular Evolution</i> , 2015, 81, 210-217.	0.8	33
68	Blood neutrophil to lymphocyte ratio as a predictor in patients with advanced hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy. <i>Hepatology Research</i> , 2015, 45, 949-959.	1.8	40
69	Hepatocellular Carcinoma with β -Catenin Mutation: Imaging and Pathologic Characteristics. <i>Radiology</i> , 2015, 275, 708-717.	3.6	74
70	Identification of a unique hepatocellular carcinoma line, Li-7, with CD13(+) cancer stem cells hierarchy and population change upon its differentiation during culture and effects of sorafenib. <i>BMC Cancer</i> , 2015, 15, 260.	1.1	22
71	Severe Veno-occlusive Disease/Sinusoidal Obstruction Syndrome After Deceased-donor and Living-donor Liver Transplantation. <i>Transplantation Proceedings</i> , 2014, 46, 3523-3535.	0.3	25
72	Molecular Biology of Liver Cancer Stem Cells. <i>Liver Cancer</i> , 2014, 3, 71-84.	4.2	146

#	ARTICLE	IF	CITATIONS
73	Disulfiram Eradicates Tumor-Initiating Hepatocellular Carcinoma Cells in ROS-p38 MAPK Pathway-Dependent and -Independent Manners. PLoS ONE, 2014, 9, e84807.	1.1	70
74	The transcription factor SALL4 regulates stemness of EpCAM-positive hepatocellular carcinoma. Journal of Hepatology, 2014, 60, 127-134.	1.8	124
75	Gd-EOB-DTPA-enhanced magnetic resonance imaging and alpha-fetoprotein predict prognosis of early-stage hepatocellular carcinoma. Hepatology, 2014, 60, 1674-1685.	3.6	104
76	Orchestration of hepatocellular carcinoma development by diverse liver cancer stem cells. Journal of Gastroenterology, 2014, 49, 1105-1110.	2.3	40
77	Discrete nature of EpCAM ⁺ and CD90 ⁺ cancer stem cells in human hepatocellular carcinoma. Hepatology, 2013, 57, 1484-1497.	3.6	241
78	Cancer stem cells in the development of liver cancer. Journal of Clinical Investigation, 2013, 123, 1911-1918.	3.9	452
79	Molecular mechanisms of hepatocarcinogenesis in chronic hepatitis C virus infection. Journal of Gastroenterology and Hepatology (Australia), 2011, 26, 960-964.	1.4	30
80	Oncostatin M Renders Epithelial Cell Adhesion Molecule ⁺ Positive Liver Cancer Stem Cells Sensitive to 5-Fluorouracil by Inducing Hepatocytic Differentiation. Cancer Research, 2010, 70, 4687-4697.	0.4	88
81	Activation of lipogenic pathway correlates with cell proliferation and poor prognosis in hepatocellular carcinoma. Journal of Hepatology, 2009, 50, 100-110.	1.8	141
82	EpCAM-Positive Hepatocellular Carcinoma Cells Are Tumor-Initiating Cells With Stem/Progenitor Cell Features. Gastroenterology, 2009, 136, 1012-1024.e4.	0.6	1,029
83	EpCAM and Î±-Fetoprotein Expression Defines Novel Prognostic Subtypes of Hepatocellular Carcinoma. Cancer Research, 2008, 68, 1451-1461.	0.4	689
84	Identification of novel candidate tumour marker genes for intrahepatic cholangiocarcinoma. Journal of Hepatology, 2008, 49, 207-216.	1.8	70
85	Activation of Hepatic Stem Cell Marker EpCAM by Wnt ¹ -Catenin Signaling in Hepatocellular Carcinoma. Cancer Research, 2007, 67, 10831-10839.	0.4	405
86	Comprehensive Gene Expression Profile of a Normal Human Liver. Biochemical and Biophysical Research Communications, 2000, 269, 110-116.	1.0	77